Comparative Effectiveness Regulations and Pharmaceutical Innovation
Year of publication: |
2010
|
---|---|
Authors: | Vernon, John A. ; Golec, Joseph H. ; Stevens, J. Stedman. |
Published in: |
PharmacoEconomics. - Springer Healthcare | Adis, ISSN 1170-7690. - Vol. 28.2010, 10, p. 877-887
|
Publisher: |
Springer Healthcare | Adis |
Subject: | Clinical-trial-design | Health-policy | Randomised-controlled-trials | Research-and-development | Treatment-outcome |
Extent: | application/pdf text/html |
---|---|
Type of publication: | Article |
Classification: | C - Mathematical and Quantitative Methods ; D - Microeconomics ; I - Health, Education, and Welfare ; Z - Other Special Topics ; I1 - Health ; I19 - Health. Other ; I18 - Government Policy; Regulation; Public Health ; I11 - Analysis of Health Care Markets |
Source: |
-
Mullins, C. Daniel., (2010)
-
Comparative Effectiveness Research: The View from a Pharmaceutical Company
Berger, Marc L., (2010)
-
Chalkidou, Kalipso, (2010)
- More ...
-
The Case for Less, Not More, US FDA Regulation
Vernon, John A., (2011)
-
An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending
Vernon, John A., (2009)
-
Drug development costs when financial risk is measured using the Fama–French three‐factor model
Vernon, John A., (2010)
- More ...